3 completed, 1 recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow Heplisav-B: new trials by email Literature Review of Heplisav-B trials Research Report on Heplisav-B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B] - Hepatitis B, Chronic Hepatitis B | Phase 1 | Recruiting | University of Maryland, Baltimore | 10 | 2025-10-16 | 2025-10-20 |
| A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate HEPLISAV B; TherVacB, TherVacB - Chronic Hepatitis B | Phase 1 | Completed | Universitätsklinikum Hamburg-Eppendorf | 26 | 2024-01-23 | 2026-06-04 |
| Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients Heplisav-B - Hepatitis B | Phase 1 | Completed | Baylor Research Institute | 10 | 2019-12-03 | 2022-03-11 |
| HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis HEPLISAV-B® - End Stage Renal Disease on Hemodialysis (Diagnosis) | Phase 1 | Completed | Dynavax Technologies Corporation | 119 | 2019-04-22 | 2024-08-09 |
Hepatitis B (3) · Hepatitis B, Chronic (2) · Disease (1) · Kidney Failure, Chronic (1)
Baylor Research Institute (1) · Dynavax Technologies Corporation (1) · University of Maryland, Baltimore (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (3) · Germany (1)
Lydia Tang, MBChB (1) · Marylyn M Addo, Prof (1) · Robert Perrillo, MD, FAASLD (1)